News Headlines Article

Providers still skittish of CMS’ renal ACO initiative
Modern Healthcare

With just a few months before its launch, some providers are expressing frustration with a CMS initiative aimed at testing innovative payment and care-delivery models specifically geared toward patients with end-stage renal disease. Too many questions remain about key details and the framework offers too little potential for success.

The treatment of end-stage renal disease, or ESRD, cost Medicare $34 billion in 2011, about 6% of all Medicare spending. Hemodialysis for ESRD costs the program about $88,000 a year per patient.